Altered expression and mutation of GRIM-19 has been observed in various tumors including lung cancer [11], hepatocellular carcinoma (HCC) [12], breast cancer [13], glioma [14], renal cell carcinoma (RCC) [15] and HNSCC [16]. This evidence concerns the gene NDUFA13 and head and neck squamous cell carcinoma.